Our DARPin platform has vast applicability across a range of diseases. Explore our pipeline:
Immune Cell Engagers
- The Company continues to evaluate potential business opportunities for abicipar, outside of Molecular Partners.
- Molecular Partners was informed by Novartis that the Emergency Use Authorization (EUA) application from the U.S. Food and Drug Administration (FDA) for ensovibep was withdrawn effective January 25th, 2023. As previously disclosed, ensovibep is not presently in clinical development.